WO2009041765A1 - Pharmaceutical composition containing esomeprazole - Google Patents
Pharmaceutical composition containing esomeprazole Download PDFInfo
- Publication number
- WO2009041765A1 WO2009041765A1 PCT/KR2008/005451 KR2008005451W WO2009041765A1 WO 2009041765 A1 WO2009041765 A1 WO 2009041765A1 KR 2008005451 W KR2008005451 W KR 2008005451W WO 2009041765 A1 WO2009041765 A1 WO 2009041765A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- esomeprazole
- solid dispersion
- stability
- free base
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Definitions
- each polymer was mixed with esomeprazole free base at a weight ratio of 1:3 or 1:6, and the each mixture was compacted with roller compacter and granulated. All conditions were the same to counterbalance temperature happening during compaction. Stability test was performed by storing made granules in brown plastic bottles at accelerated conditions (4O 0 C, 75%RH) for one week, and formed impurities were analyzed with HPLC. The results were collectively shown in tables 2 and 3.
- HPMC 5cp and 15cp mean hydroxypropylmethylcellulose which viscosity is about 5 cP or 15 cP, respectively, when measured at 2O 0 C as 2 wt% water solution.
- L-HPC means low-substituted hydroxypropylcellulose
- HPC means hy- droxypropylcellulose.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to esomeprazole free base or its alkali salt-containing composition which stability is improved and is easy to manufacture.
Description
Description
PHARMACEUTICAL COMPOSITION CONTAINING ES-
OMEPRAZOLE
Technical Field
[1] The present invention relates to esomeprazole free base or its alkali salt-containing pharmaceutical preparation which stability is improved. Background Art
[2] Esomeprazole ((S
)-5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-3H-benzoimidaz ole) is a proton pump inhibitor which is used in the treatment of peptic ulcer, gastroesophageal reflux etc. The free base of the esomeprazole is not good in terms of storage stability and physical properties. Concretely, esomeprazole free base's melting point is about 450C so that it is much difficult to formulate, and its stability is so bad that total impurities increase to about 1% after stored for two months in conditions of 25°C/60%RΗ. In addition, the esomeprazole's stability is much worse in alkali condition than acidic or neutral condition.
[3] A commercially available product uses esomeprazole magnesium salt to improve stability and physical properties of the esomeprazole free base. However, the magnesium salt of esomeprazole also does not have enough good stability, and thus many studies have been performed to improve the stability of the salt. Disclosure of Invention Technical Problem
[4] Accordingly, the object of the present invention is to provide an esomeprazole free base or its alkali salt-containing pharmaceutical composition which stability is improved and is simple to manufacture. Technical Solution
[5] To achieve the object, the present invention provides a solid dispersion comprising esomeprazole free base or its alkali salt; alkaline material; and hydrophilic polymer selected from the group consisting of polyvinylpyrrolidone, vinylpyrrolidone- vinylacetate copolymer and their mixture.
[6] Preferably, the present invention provides said solid dispersion wherein the alkaline material is MgO or Mg(OH) .
[7] The prevent invention provides also an esomeprazole-containing pharmaceutical composition having improved stability, which comprises said solid dispersion.
[8] Hereinafter, the esomeprazole-containing solid dispersion and the pharmaceutical composition comprising the solid dispersion according to the present invention will be
described in more detail.
[9] The present invention provides a solid dispersion comprising esomeprazole free base or its alkali salt; alkaline material; and hydrophilic polymer selected from the group consisting of polyvinylpyrrolidone, vinylpyrrolidone-vinylacetate copolymer and their mixture.
[10] The present invention is based on the fact that the stability of the solid dispersion made of esomeprazole free base or its alkali salt, alkaline material and hydrophilic polymer is much better than the simple mixture of esomeprazole free base or its alkali salt, alkaline material and hydrophilic polymer. The present invention is based on also the surprising fact that polyvinylpyrrolidone, vinylpyrrolidone-vinylacetate copolymer or their mixture is very much better for esomeprazole's stability in the solid dispersion than other polymers.
[11] The solid dispersion according to the present invention comprises esomeprazole free base or its alkali salt as active agent, and alkali metal salt or alkali earth metal salt such as esomeprazole's sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum or lithium salt and esomeprazole salt made from basic amino acid such as arginine, lysine or glycine, ammonia, the first, second or tertiary amine and so on may be used as the esomeprazole's alkali salt.
[12] The solid dispersion according to the present invention comprises also polyvinylpyrrolidone, vinylpyrrolidone-vinylacetate copolymer or their mixture as hydrophilic polymer, which forms and keeps solid dispersion state. The polyvinylpyrrolidone and vinylpyrrolidone-vinylacetate copolymer are much better in improving the stability of esomeprazole than other hydrophilic polymers.
[13] Further, the solid dispersion according to the present invention comprises alkaline material to make the micro-environment of the inside of the solid dispersion alkaline for the purpose of improving the stability of esomeprazole. Examples of the alkaline material include, but are not limited to, inorganic alkaline material like hydroxide, oxide, carbonate or phosphate made from alkali metal or alkali earth metal such as sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum or lithium; and organic alkaline material like basic amino acid such as arginine, lysine or glycine, ammonia, the first, second or tertiary amine, cyclic amine, meglumine (N-methyl-D-glucamine). Among these alkaline materials, magnesium oxide and magnesium hydroxide are much better in terms of esomeprazole's stability than other alkaline materials.
[14] Therefore, most preferably, the present invention provides the solid dispersion comprising esomeprazole free base or its alkali salt; polyvinylpyrrolidone, vinylpyrrolidone-vinylacetate copolymer or their mixture; and magnesium oxide or magnesium hydroxide.
[15] In case that polyvinylpyrrolidone or vinylpyrrolidone-vinylacetate copolymer and magnesium oxide or hydroxide are added to improve the stability of esomeprazole, it is preferable that polyvinylpyrrolidone or vinylpyrrolidone-vinylacetate copolymer; magnesium oxide or hydroxide; and esomeprazole are mixed homogenously and minutely. In this case, making solid dispersion can very much improve the stability of esomeprazole.
[16] This solid dispersion can be made by dissolving or suspending esomeprazole free base or its alkali salt; polyvinylpyrrolidone, vinylpyrrolidone-vinylacetate copolymer or their mixture; and magnesium oxide or hydroxide together in a suitable solvent like water, ethanol, isopropanol, acetone, methanol, or methylene chloride, and then drying the solution or suspension in a condition to keep the mixture's homogeneity.
[17] The solid dispersion according to the present invention may be made by drying the solution or suspension only, or by spray-drying the solution or suspension onto a pharmaceutically acceptable other excipient (for example, lactose, microcrystalline cellulose, sucrose, starch etc.).
[18] Besides said methods, the solid dispersion according to the present invention may be made by making a solid dispersion comprising esomeprazole free base or its alkali salt and polyvinylpyrrolidone, vinylpyrrolidone-vinylacetate copolymer or their mixture, and then spray-drying magnesium oxide or hydroxide onto the solid dispersion; or by making a solid dispersion comprising esomeprazole free base or its alkali salt and magnesium oxide or hydroxide, and then spray-drying polyvinylpyrrolidone, vinylpyrrolidone-vinylacetate copolymer or their mixture onto the solid dispersion. However, the method to dissolve or suspend three components together for making a solid dispersion is most preferable in terms of homogeneity of mixture, and, consequently, in terms of stability.
[19] Therefore, preferably, the present invention provides also a method for manufacturing esomeprazole-containing solid dispersion which has improved stability, wherein the method comprises (Sl) preparing a solution or suspension comprising esomeprazole free base or its alkali salt; magnesium oxide or hydroxide; and polyvinylpyrrolidone, vinylpyrrolidone-vinylacetate copolymer or their mixture; and (S2) drying the solution or suspension.
[20] More preferably, the present invention provides said method for manufacturing esomeprazole-containing solid dispersion which has improved stability, wherein the LOD (loss on drying, 1050C, the weight of test sample is 5g) in the drying process of the (S2) step is less than 2% (0.5-2%), more preferably less than 1.5% (0.5-1.5%).
[21] Preferably, in the method, a small amount of alkaline material may be further added into the solution or suspension to block esomeprazole from degrading during the process for making the solid dispersion.
[22] The present invention provides also a pharmaceutical composition comprising the solid dispersion, and the pharmaceutical composition may comprise pharmaceutically acceptable excipients in addition to the solid dispersion. Examples of the pharmaceutically acceptable excipient include, but are not limited to, diluent, favoring agent, binder, preservative, disintegrator, lubricant, and filler.
[23] The present invention provides also a pharmaceutical preparation which is made by coating said pharmaceutical composition with enteric polymer (for example, methacrylic acid copolymer dispersion, hydroxypropylmethylcellulose phthalate, hyd roxypropylmethylcellulose acetate succinate, cellulose acetate phthalate, or polyvinyl acetate phthalate), and, more preferably, said pharmaceutical preparation which has another coating layer made of hydrophilic polymer (hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, vinylpyrrolidone-vinylacetate copolymer, polyvinylalcohol, polyvinylalcohol-polyethylene glycol copolymer, hy- droxymethylcellulose, hydroxyethylcellulose, hydroxyethylmethylcellulose, polyvinylacetate, polyalkene oxide, polyalkene glycol, polyoxyethylene-poly- oxypropylene polymer, diethylamino acetate, aminoalkylmethacrylate copolymer, sodium alginate, gelatin etc.) between the pharmaceutical composition and the enteric coating layer.
Advantageous Effects
[24] The present invention provides an esomeprazole free base or its alkali salt-containing pharmaceutical composition which has improved stability and is easy to manufacture. Brief Description of the Drawings
[25] Figure 1 is graphs showing pharmacokinetic absorption evaluation results performed before a meal with a preferable example according to the present invention and Nexium 40mg, comparative example.
[26] Figure 2 is graphs showing pharmacokinetic absorption evaluation results performed after a meal with a preferable example according to the present invention and Nexium 40mg, comparative example. Mode for the Invention
[27] Hereinafter, the present invention is described in considerable detail to help those skilled in the art understand the present invention. However, the following examples are offered by way of illustration and are not intended to limit the scope of the invention. It is apparent that various changes may be made without departing from the spirit and scope of the invention or sacrificing all of its material advantages.
[28]
[29] Experimental example 1> Selection of polymer
[30] As shown in table 1 below, each polymer was mixed with esomeprazole free base at
a weight ratio of 1:3 or 1:6, and the each mixture was compacted with roller compacter and granulated. All conditions were the same to counterbalance temperature happening during compaction. Stability test was performed by storing made granules in brown plastic bottles at accelerated conditions (4O0C, 75%RH) for one week, and formed impurities were analyzed with HPLC. The results were collectively shown in tables 2 and 3.
[31] The analysis of impurities was performed as follows: each granule was pulverized, and an amount equivalent to about 20mg of esomeprazole was weighed and put in 10OmL of flask. 1OmL of methanol was added in the flask, and mixed well. Then 2OmL of phosphate buffer solution (pH 11.0) was added, and the flask was sonicated. Water was added to make the same volume, and then the solution was membrane- filtered to make a test sample. Then, the test sample was analyzed in HPLC conditions described below. Peak area of less than 0.05% was not included in the calculation.
[32] [HPLC Conditions] [33] Detector: UV spectrophotometer (detection wavelength 302nm) [34] Column: Cosmosil 5C18-AR-II, 4.6xl50mm or its equivalent column [35] Mobile phase: (Gradient) [36] A: a mixture of acetonitrile, phosphate buffer solution (pH 7.6) and water (10 / 10 / 80)
[37] B: a mixture of acetonitrile, phosphate buffer solution (pH 7.3) and water (80 I I I 19)
[38] Injection volume: 20 uL [39] Flow rate: l.OmL/min [40] Table 1 [Table 1] [Table ]
[41] In the table 1, HPMC 5cp and 15cp mean hydroxypropylmethylcellulose which viscosity is about 5 cP or 15 cP, respectively, when measured at 2O0C as 2 wt% water
solution. L-HPC means low-substituted hydroxypropylcellulose, and HPC means hy- droxypropylcellulose.
[42] Table 2 [Table 2] [Table ]
[43] Table 3 [Table 3] [Table ]
[44] As shown in the tables 1 and 2, the compacted mixture using HPMC 5cp was the most stable in case of forming compacted mixture of esomeprazole free base and hy- drophilic polymer for solid dispersion.
[45] [46] Experimental example 2> Manufacture and evaluation of solid dispersion [47] Solid dispersions were made according to ingredients and contents of table 4 below. Example 1 was made as follows: polyvinylpyrrolidone was dissolved in ethanol, to which NaOH water solution was added and then mixed. Esomeprazole free base was dissolved in the mixed solution. Then lactose and colloidal silicon dioxide were added to the solution and mixed. The solution was dried at 4O0C and granulated to make solid dispersion granules. Example 2 was made as follows: polyvinylpyrrolidone was dissolved in ethanol, to which esomeprazole free base was dissolved. Then magnesium oxide and colloidal silicon dioxide were added to the solution and mixed. The solution was dried at 4O0C and granulated to make solid dispersion granules. Example 3 was
made as follows: hydroxypropylmethylcellulose (5 cP) was dissolved in ethanol, to which NaOH water solution was added. Esomeprazole free base was dissolved in the solution. Then magnesium oxide and colloidal silicon dioxide were added to the solution and mixed. The solution was dried at 4O0C and granulated to make solid dispersion granules.
[48] Table 4 [Table 4] [Table ]
[49] The stability of examples 1 to 3 was evaluated according to the same method as that of experimental example 1. Results were shown in table 5 below. [50] Table 5 [Table 5] [Table ]
[51] As shown in the table 5, the solid dispersion of example 1 having no MgO showed much increase of impurities after only 1 week of the accelerated stability test. In addition, the stability of the solid dispersion using PVP was much better than the solid dispersion using HPMC 5 cP which showed the best stability in experimental example 1
[52] [53] Experimental example 3> Stability test of simple mixture [54] Simple mixture, a test sample was made by simply mixing according to the ingredients and contents of table 6.
[55] Table 6 [Table 6] [Table ]
[56] The stability of examples 4 to 6 was evaluated according to the same method as that of experimental example 1. Results were shown in table 7 below. [57] Table 7 [Table 7] [Table ]
[58] As shown in the table 7, simple mixture of ingredients did not show improved stability of esomeprazole.
[59] [60] Experimental example 4> Evaluation of alkaline material [61] As shown in table 8 below, the effect of the kind of alkaline material on stability was evaluated in esomeprazole-containing solid dispersion according to the present invention. PVP was dissolved in ethanol, to which esomeprazole free base was dissolved. Each alkaline material and colloidal silicon dioxide were added to the solution and mixed well. The solution was dried at 4O0C, and then granulated to make
solid dispersion granules.
[62] Table 8 [Table 8] [Table ]
[63] The stability of examples 7 to 13 was evaluated according to the same method as that of experimental example 1. Results were shown in table 9 below. [64] Table 9
[Table 9] [Table ]
[65] As shown in table 9, the solid dispersion using MgO was the most stable. [66] [67] Experimental example 5> Evaluation of content of each ingredient [68] Esomeprazole free base-containing solid dispersion was made according to the ingredients and contents of table 10 below. Polyvinylpyrrolidone was dissolved in ethanol, to which NaOH water solution was added. Esomeprazole free base was added to the mixed solution, and then MgO and colloidal silicon dioxide were added and mixed. The solution was dried at 4O0C and granulated to make solid dispersion granules.
[69] Table 10 [Table 10] [Table ]
[70] The stability of examples 14 to 18 was evaluated according to the same method as that of experimental example 1. Results were shown in table 11 below.
[71] Table 11 [Table 11] [Table ]
[72] As shown in the table 11, colloidal silicon dioxide is thought not to affect the stability of esomeprazole when comparing example 15 with example 18. In addition, the more the amount of MgO was, the better the stability of esomeprazole-containing solid dispersion was, when comparing example 14 and example 15, and the decrease of PVP content caused the increase of total impurities when comparing example 15 and example 17.
[73] [74] Experimental example 6> Stability evaluation according to water content in process steps
[75] Esomeprazole free base-containing pharmaceutical composition was made according to the table 12 below, and only drying process was changed in examples a to e to evaluate the affect of drying process on stability.
[76] Table 12
[Table 12] [Table ]
[77] Examples a to e were made as follows: povidone was dissolved in ethanol, to which magnesium oxide was suspended and then esomeprazole was dissolved. The solution was coated onto spherical sugars by using a fluid bed coater to make solid dispersion granules. Then the granules were dried (drying after the first coating). The granules were again coated with HPMC to make a separating layer and then dried (drying after the second coating). Then the granules were again coated with methacrylic acid copolymer dispersion to make an enteric coating layer, and dried (drying after the third coating) to make esomeprazole free base-containing granules. LOD (Moisture Balance (Precisa, XM60), drying temperature 1050C, Auto stop, sample weight 5g) measured after each drying step were shown in table 13 below.
[78] Table 13
[Table 13] [Table ]
[79] Results of stability test using the examples a to e were shown in tables 14 and 15 below. Table 14 shows results of samples packed with PTP alu-alu, stored for 1 week at harsh storage condition (6O0C, 75%RH), and table 15 shows results of samples packed with PTP alu-alu, stored for 6 months at accelerated storage condition (4O0C, 75%RH).
[80] Table 14 [Table 14] [Table ]
[81] Table 15
[Table 15] [Table ]
[82] As shown in the tables 14 and 15, examples d and e showed greatly improved stability compared to other batch not controlling water content of coated granules in each process. Particularly, controlling water content of the first drying step among three drying processes severely affected stability, even if water content control in all coating processes were important. Drying after the first coating is preferably performed until LOD is less than 2%, more preferably less than 1.5%.
[83] [84] Experimental example 7> Evaluation of pharmacokinetic absorption [85] Enteric-coated tablets, test samples were made according to tables 16 and 17 to evaluate pharmacokinetic absorption of pharmaceutical preparations of the present invention. Concretely, povidone was dissolved in ethanol, to which NaOH water solution was added. Then esomeprazole was dissolved in the solution and mixed well. Some portion of magnesium oxide was suspended in the solution. The solution was sprayed onto colloidal silicon dioxide and magnesium oxide in fluid bed to make granules. The granules were mixed with other ingredients and tabletted to make a core tablet before coating. Then, the core tablets were coated with HPMC to make a separating layer by a tablet coater. The coated tablet was again enteric-coated with HPMC P(HP-50) to make example A, and with methacrylic acid ethylacrylate copolymer (1:1) to make example B. [86] Table 16
[Table 16] [Table ]
[87] Table 17 [Table 17] [Table ]
[88] Capsule preparation according to the present invention was made like table 18. The below two examples were made by the same method except for spherical sugar used as seed. 850-710 um of spherical sugar was used as seed for example C, and 710-600 um of spherical sugar was used as seed for example D. Povidone was dissolved in ethanol,
to which magnesium oxide was suspended. Esomeprazole was dissolved in the solution. The solution was sprayed onto spherical sugar in a fluid bed to make pellets coated with active agent. These pellets were coated with HPMC to make a separating layer which blocks contact between active agent and enteric substance. Then the enteric-coated pellet was made with methacrylic acid copolymer dispersion.
[89] Table 18 [Table 18] [Table ]
[90] Pharmacokinetic absorption test was performed with the examples A to D and commercially available product, Nexium 40mg tablet (AstraZeneca, comparative example). Results of pharmacokinetic test performed before a meal were shown in table 19 (result of enteric-coated tablet) and 20 (result of capsule), respectively. Results of the tables 19 and 20 were mean value of values obtained after administering to 12 about 30-year-old men.
[91] Table 19
[Table 19] [Table ]
[92] In tablets, example A coated with HPMC P (HP-50) which dissolve at pH 5.0 showed higher Cmax and AUC than example B coated with methacrylic acid copolymer dispersion which dissolves at pH 5.5. When compared to the comparative example (commercially available product), example A showed 71.1% of Cmax and 114.4% of AUC, and example B showed 60.0% of Cmax and 88.3% of AUC.
[93] Table 20 [Table 20] [Table ]
[94] In capsules, example D using 710-600 um (diameter) of spherical sugar as seed showed Cmax and AUC more similar to the comparative example (commercially available product) than example C using 850-710 um (diameter) of spherical sugar as seed. When compared to the comparative example (commercially available product), example C showed 87.9% of Cmax and 106.6% of AUC, and example D showed 108.4% of Cmax and 96.1% of AUC. Result of example D was shown in figure 1.
[95] To evaluate pharmacokinetic absorption after a meal, pharmacokinetic absorption patterns of the comparative example and example D were evaluated after High-fat breakfast (750kcal, fat was about 50% of total calories (41.7g)) was ingested. Results were shown in table 21 below and figure 2.
[96] Table 21
[Table 21] [Table ]
[97] In after-meal bioequivalent test to evaluate the effect of food, the example D having improved stability according to the present invention showed similar absorption ratio to the comparative example (commercially available product). Example D showed 98.8% of Cmax and 95.7% of AUC compared to the comparative example.
[98] In the pharmacokinetic absorption test, LC/MS/MS was used for detecting es- omeprazole in plasma, and sildenafil was used as internal standard. LC conditions were like "Column - YMC Hydrosphere C18; Mobile phase - 1OmM Ammonium Acetate : Acetonitrile = 10 : 90 (v/v); Flow rate - 0.25mL/min; Injection volume - lOuL; Sample temperature - 1O0C; and column temperature - 3O0C", and MS conditions were like "Ionizing method - electrospray ionization (ESI) in Positive ion mode; MRM (Multiple Reaction Monitoring) - Esomeprazole [M+H]+ 326.2 → 198.1, Sildenafil [M+H]+ 475.2 → 283.2."
Claims
Claims
[1] A solid dispersion comprising esomeprazole free base or its alkali salt; alkaline material; and hydrophilic polymer selected from the group consisting of polyvinylpyrrolidone, vinylpyrrolidone-vinylacetate copolymer and their mixture.
[2] The solid dispersion of claim 1, wherein the alkaline material is MgO or
Mg(OH)2.
[3] Esomeprazole-containing pharmaceutical composition having improved stability, comprising the solid dispersion of claim 1 or 2.
[4] A method for manufacturing esomeprazole-containing pharmaceutical composition having improved stability, comprising
(51) preparing solution or suspension comprising esomeprazole free base or its alkali salt; magnesium oxide or magnesium hydroxide; and polyvinylpyrrolidone, vinylpyrrolidone-vinylacetate copolymer or their mixture; and
(52) drying the solution or suspension.
[5] The method of claim 4, wherein the drying of (S2) step is performed until LOD
(loss on drying, 1050C, test sample weight 5g) is less than 2%.
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08833010A EP2205218A4 (en) | 2007-09-28 | 2008-09-16 | PHARMACEUTICAL COMPOSITION CONTAINING ESOMEPRAZOLE |
| AU2008304033A AU2008304033B2 (en) | 2007-09-28 | 2008-09-16 | Pharmaceutical composition containing esomeprazole |
| CN200880108483A CN101808622A (en) | 2007-09-28 | 2008-09-16 | Pharmaceutical composition containing esomeprazole |
| CA2704132A CA2704132A1 (en) | 2007-09-28 | 2008-09-16 | Pharmaceutical composition containing esomeprazole |
| US12/680,236 US20110184024A1 (en) | 2007-09-28 | 2008-09-16 | Pharmaceutical Composition Containing Esomeprazole |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20070098095 | 2007-09-28 | ||
| KR10-2007-0098095 | 2007-09-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2009041765A1 true WO2009041765A1 (en) | 2009-04-02 |
Family
ID=40511627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2008/005451 Ceased WO2009041765A1 (en) | 2007-09-28 | 2008-09-16 | Pharmaceutical composition containing esomeprazole |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20110184024A1 (en) |
| EP (1) | EP2205218A4 (en) |
| KR (1) | KR101104349B1 (en) |
| CN (3) | CN103126998A (en) |
| AU (1) | AU2008304033B2 (en) |
| CA (1) | CA2704132A1 (en) |
| WO (1) | WO2009041765A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130115253A1 (en) * | 2011-11-07 | 2013-05-09 | Mahendra R. Patel | Sustained Release Suspension Preparation For Dextromethorphan |
| CN115721611A (en) * | 2022-12-09 | 2023-03-03 | 北京斯利安药业有限公司 | Vonola fumarate dry suspension and preparation method thereof |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2671487C2 (en) * | 2013-05-10 | 2018-11-01 | СиТиСи БАЙО, ИНК. | Preparation in form of film containing free donepezilum base and method for its manufacture |
| CN103386133A (en) * | 2013-07-09 | 2013-11-13 | 重庆莱美药业股份有限公司 | Oral instant preparation of proton pump inhibitor and preparation method thereof |
| KR101658275B1 (en) * | 2014-01-20 | 2016-09-20 | 대원제약주식회사 | Small Pharmaceutical Preparations Comprising S-omeprazole |
| KR101723266B1 (en) * | 2014-08-13 | 2017-04-05 | 영남대학교 산학협력단 | Immediate release oral composition comprising non-steroidal anti-inflammatory drug and proton pump inhibitor, and method for preparing the same |
| KR101537263B1 (en) * | 2014-09-29 | 2015-07-17 | 주식회사 서울제약 | A Orally Disintegrating Film masked bitter taste of ondansetron |
| KR102408645B1 (en) * | 2015-12-24 | 2022-06-14 | (주)휴온스 | Improved stability double-coated tablet Composition including S-omeprazole and manufacturing method thereof |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| KR102006777B1 (en) | 2018-01-29 | 2019-10-08 | 주식회사 종근당 | Pharmaceutical formulation comprising esomeprazole and sodium bicarbonate |
| KR102080023B1 (en) | 2018-01-29 | 2020-02-21 | 주식회사 종근당 | Stable pharmaceutical composition comprising esomeprazole and sodium bicarbonate |
| JP2021533177A (en) | 2018-08-23 | 2021-12-02 | チョン クン ダン ファーマシューティカル コーポレイション | A pharmaceutical formulation with excellent dissolving properties, including esomeprazole and sodium bicarbonate. |
| JP7321744B2 (en) * | 2019-03-22 | 2023-08-07 | キョーリンリメディオ株式会社 | Enteric-coated solid preparation containing stabilized esomeprazole magnesium hydrate |
| BR112022001287A2 (en) | 2019-07-26 | 2022-04-12 | Chong Kun Dang Pharmaceutical Corp | pharmaceutical composition |
| CN110988180A (en) * | 2019-12-19 | 2020-04-10 | 山东达因海洋生物制药股份有限公司 | Method for analyzing related substances of esomeprazole magnesium based on hybrid mass spectrometry |
| KR102573842B1 (en) | 2020-02-21 | 2023-09-01 | 주식회사 종근당 | Pharmaceutical composition comprising esomeprazole and sodium bicarbonate having improved drug release properties |
| KR20210012881A (en) | 2020-02-28 | 2021-02-03 | 주식회사 종근당 | Pharmaceutical formulation comprising esomeprazole and sodium bicarbonate having improved drug release properties |
| CN113533597A (en) * | 2021-07-29 | 2021-10-22 | 南京西默思博检测技术有限公司 | Method for determining esomeprazole in human plasma |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6090827A (en) * | 1997-05-28 | 2000-07-18 | Astrazeneca Ab | Pharmaceutical formulation of omeprazole |
| US6428810B1 (en) * | 1998-11-05 | 2002-08-06 | Astrazeneca Ab | Pharmaceutical formulation comprising omeprazole |
| US20030113376A1 (en) * | 1997-11-14 | 2003-06-19 | Chih-Ming Chen | Omeprazole formulation |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19918434A1 (en) * | 1999-04-23 | 2000-10-26 | Basf Ag | Storage-stable solid proton pump inhibitor formulation useful e.g. for treating duodenal ulcers, comprises amorphous active agent embedded in auxiliary matrix |
| US6749867B2 (en) | 2000-11-29 | 2004-06-15 | Joseph R. Robinson | Delivery system for omeprazole and its salts |
| US20080146615A1 (en) * | 2004-12-20 | 2008-06-19 | Dr. Reddy's Laboratories Limited | Pharmaceutical Compositions Comprising Amorphous Benzimidazole Compounds |
| WO2006066932A1 (en) * | 2004-12-24 | 2006-06-29 | Lek Pharmaceuticals D.D. | Stable pharmaceutical composition comprising an active substance in the form of solid solution |
| KR20070069567A (en) * | 2005-12-28 | 2007-07-03 | 에스케이케미칼주식회사 | S-omeprazole-containing clathrate composite with excellent storage stability and preparation method thereof |
-
2008
- 2008-09-16 KR KR1020080090692A patent/KR101104349B1/en not_active Expired - Fee Related
- 2008-09-16 CA CA2704132A patent/CA2704132A1/en not_active Abandoned
- 2008-09-16 AU AU2008304033A patent/AU2008304033B2/en not_active Ceased
- 2008-09-16 CN CN201310044975XA patent/CN103126998A/en active Pending
- 2008-09-16 US US12/680,236 patent/US20110184024A1/en not_active Abandoned
- 2008-09-16 CN CN201510263168.6A patent/CN104940127A/en active Pending
- 2008-09-16 EP EP08833010A patent/EP2205218A4/en not_active Withdrawn
- 2008-09-16 WO PCT/KR2008/005451 patent/WO2009041765A1/en not_active Ceased
- 2008-09-16 CN CN200880108483A patent/CN101808622A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6090827A (en) * | 1997-05-28 | 2000-07-18 | Astrazeneca Ab | Pharmaceutical formulation of omeprazole |
| US20030113376A1 (en) * | 1997-11-14 | 2003-06-19 | Chih-Ming Chen | Omeprazole formulation |
| US6428810B1 (en) * | 1998-11-05 | 2002-08-06 | Astrazeneca Ab | Pharmaceutical formulation comprising omeprazole |
Non-Patent Citations (1)
| Title |
|---|
| See also references of EP2205218A4 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130115253A1 (en) * | 2011-11-07 | 2013-05-09 | Mahendra R. Patel | Sustained Release Suspension Preparation For Dextromethorphan |
| CN115721611A (en) * | 2022-12-09 | 2023-03-03 | 北京斯利安药业有限公司 | Vonola fumarate dry suspension and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103126998A (en) | 2013-06-05 |
| KR101104349B1 (en) | 2012-01-16 |
| CN104940127A (en) | 2015-09-30 |
| CA2704132A1 (en) | 2009-04-02 |
| CN101808622A (en) | 2010-08-18 |
| KR20090033000A (en) | 2009-04-01 |
| EP2205218A1 (en) | 2010-07-14 |
| EP2205218A4 (en) | 2010-11-17 |
| AU2008304033B2 (en) | 2014-05-01 |
| AU2008304033A1 (en) | 2009-04-02 |
| US20110184024A1 (en) | 2011-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2008304033B2 (en) | Pharmaceutical composition containing esomeprazole | |
| EP2645996B1 (en) | Method for producing a pharmaceutical composition comprising proton pump inhibitors | |
| US6096340A (en) | Omeprazole formulation | |
| KR102408645B1 (en) | Improved stability double-coated tablet Composition including S-omeprazole and manufacturing method thereof | |
| US20090324718A1 (en) | Imatinib compositions | |
| CN102119927A (en) | Enteric-coated pellet preparation of proton pump inhibitor and preparation method thereof | |
| AU5791900A (en) | Solid oral pharmaceutical formulation of modified release that contains an acid labile benzimidazole compound | |
| EP2540318A1 (en) | Sustained-release solid preparation for oral use | |
| EP2740471B1 (en) | Oral pharmaceutical composition comprising dabigatran etexilate | |
| KR102727681B1 (en) | Stable pharmaceutical formulation for oral administration comprising dexlansoprazole or a pharmaceutically acceptable salt thereof | |
| JP4127740B2 (en) | Stabilized benzimidazole compound-containing composition | |
| WO2015145462A1 (en) | Pharmaceutical compositions of dabigatran | |
| EP3646855B1 (en) | Oral solid preparation composition comprising proton pump inhibitor, oral solid preparation comprising same, and preparation method therefor | |
| JP7125790B2 (en) | Pharmaceutical composition containing dabigatran etexilate and method of preparation thereof | |
| EP2600847A1 (en) | Oral pharmaceutical formulations of esomeprazole in the form of mups (multi unit pellets system) tablets | |
| MX2013000827A (en) | Multiple unit tablet composition. | |
| EP3090732B1 (en) | Pharmaceutical composition containing clomipramine and preparation method therefor | |
| US20230310401A1 (en) | Pharmaceutical Composition Containing Dabigatran Etexilate And Preparation Method Thereof | |
| KR20200002486A (en) | Wet granulation composition, tablet comprising same, and method for preparing the tablet | |
| US20090220552A1 (en) | Formulations containing pantoprazole free acid and its salts | |
| CN117731629A (en) | Compound capsule of levamlodipine besylate and benazepril hydrochloride and preparation method thereof | |
| WO2016122421A1 (en) | Stable pharmaceutical compositions containing prasugrel base | |
| KR20200013018A (en) | Wet granulation composition comprising polaprezinc and method for preparing tablet using the same | |
| KR20200002409A (en) | Wet granulation composition comprising polaprezinc and method for preparing tablet using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 200880108483.X Country of ref document: CN |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08833010 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 12680236 Country of ref document: US |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| REEP | Request for entry into the european phase |
Ref document number: 2008833010 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2008833010 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2704132 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2924/DELNP/2010 Country of ref document: IN Ref document number: 12010500921 Country of ref document: PH |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2008304033 Country of ref document: AU |
|
| ENP | Entry into the national phase |
Ref document number: 2008304033 Country of ref document: AU Date of ref document: 20080916 Kind code of ref document: A |